Argos Therapeutics slashed its IPO price to $8 per share after initially planning go public at between $13 ad $15 per share. Read how Argos plans to spend its IPO proceeds.
LabCorp (NYSE:LH) processed more tests in the fourth quarter than it did same period in the prior year but it made less money per test and the laboratory testing and diagnostics firm's revenue and earnings results fell short of analyst estimates.
This ain't Animal House. It's all about business - with some "frat" thrown in. But can a house in Boylan Heights devoted to eight entrepreneurs known as ThinkHouse Fellows provide an additional spark to the Triangle's entrepreneurial business sector? "It's an incredible experience," one of the new residents declare. WRALTechWire's Jason Parker tours the remodeled residence and provides a detailed first-person account for our Insiders.
Argos Therapeutics is set to go public today at $8 per share. According to an updated filing with the SEC on Thursday, Argos was seeking to raise $73.312.500. But at the share price disclosed Friday morning, Argos will raise some $45 million.
Raleigh's newest hot spot for entrepreneurs - the ThinkHouse - offers shared living space for entrepreneurial "Fellows." So what's the living space look like? We have exclusive photos.
Sometimes the newest medical innovations find their inspiration from old technology. In a WRALTechWire exclusive, read how an old sewing machine marked the beginning for Wilmington medical device startup GO2.
Both The Wall Street Journal and The Financial Times are reporting that IBM is looking to sell its semiconductor manufacturing business. If so, it would be the latest move by IBM to quit manufacturing.
The record results exceeded ChannelAdvisor's expectations and marked the first time its sales had ever topped $20 million in a quarter. Read why ChannelAdvisor's sales are riding high.
The Cary company, whose software automates spending and purchasing functions for companies, narrowed its net loss to $1.2 million compared to a $2.4 million net loss in the prior year period. The company said the results were expected and were related to costs associated with acquisitions and stock-based compensation.